Navigation Links
Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
Date:3/24/2008

SAN DIEGO, Calif., March 24 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of blood substitutes, today announced that it has completed enrollment in a Phase III trial of its lead product Hemospan(R).

The completed study of 460 patients is one of two parallel Phase III clinical trials being conducted at 36 academic medical centers in the United Kingdom, Sweden, the Netherlands, Belgium, Poland and the Czech Republic. The two randomized, placebo-controlled studies, which will enroll a combined total of more than 800 elective orthopedic surgery patients, are designed to evaluate the safety and efficacy of Hemospan in preventing and treating hemodynamic instability, especially hypotension, or low blood pressure, during surgery.

"We are pleased to have completed enrollment in this Phase III study," said Dr. Robert Winslow, Chairman, President and CEO of Sangart. "This represents a major milestone for Sangart as we continue to gather evidence of Hemospan's potential to satisfy the significant and growing demand for a safe and effective agent to improve oxygen transport in clinical settings where blood is often transfused."

Sangart also announced that enrollment in the second Phase III study is progressing well and is expected to be completed in the near future.

No similar oxygen transport agents are currently on the market in Europe or the United States. Earlier clinical studies indicate that Hemospan's novel oxygen delivery mechanism has the potential to provide a safe and effective alternative to blood transfusions.

About Sangart

Sangart is a privately held San Diego-based biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as alternatives to blood transfusions.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1
'/>"/>

SOURCE Sangart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
2. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
3. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
4. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
5. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
6. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
7. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
10. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
11. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...wire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT )...athologists, oncologists and the pharmaceutical in...ke presentations at two upcoming investor conferen... will be made at the Lazard Capital Markets Sixth ...sday, November 17. The conference will be held at ...
(Date:11/7/2009)...re/ -- Patients reported C1-esterase inhibitor (C1...ing acute swelling attacks at any body location fo...ing to data presented today at the 2009 American C... Annual Meeting. The results come from a self-repo... the ongoing, prospective, open label I nternatio...
(Date:11/6/2009)...rstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bull...y approved reverse split of its common stock will .... 9, 2009 on a 1-for-15 split-adjusted basis. Oxyg...he new symbol OXBT. The stock also will have a new... effective. ,, "This reverse split was overwhel...
Breaking Medicine Technology:Clarient to Present at Upcoming Healthcare Investor Conferences in New York City 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Prospect Therapeutics In Vitro Studies Demonstrate that GCS 100 Drug Binds to and Blocks the Effects of Galectin 3 48875 1Prospect Therapeutics In Vitro Studies Demonstrate that GCS 100 Drug Binds to and Blocks the Effects of Galectin 3 48875 2Angel MedFlight Provides Air Medical Transportation for Accident Victim Needing Transport from France to U S 48871 1Angel MedFlight Provides Air Medical Transportation for Accident Victim Needing Transport from France to U S 48871 2Angel MedFlight Provides Air Medical Transportation for Accident Victim Needing Transport from France to U S 48871 3Quest Diagnostics to Speak at the Jefferies 3rd Annual Healthcare Conference 48867 1
(Date:11/9/2009)... LEBANON, Tenn., Nov. 9 Health Con...nounced it will host their inaugural Hospital O.R....010 at the Marriott Renaissance Hotel in Nashville... more than 100 hospital operating room directors a... health systems in the country. Some of the confir...
(Date:11/9/2009)... DETROIT, Nov. 9 For th... Cancer Center has been selected the most preferre...according to a survey by the National Research Cor...gi-bin/prnh/20071106/KARMANOSLOGO ) ,, The ann...naire between September 2008 and August 2009. Surv...
(Date:11/9/2009)... didn,t answer question of why this is so, however...- After a lumpectomy, women with very dense breast...ffected breast, a new study shows. , Breast den...k of developing breast cancer, and experts have su...ated with an increased risk of cancer recurrence a...
(Date:11/9/2009)... ROCHESTER, Minn., Nov. 9 /PRNewswire-USNewswire/ ... surgery for vaginal prolapse dramatically red...e findings are being presented this week at the No...ociation in Scottsdale, Ariz. ,, (Logo: http... ) ,, VIDEO ALERT : Additional audio and vide...
(Date:11/9/2009)... - Parents Support Experimental Procedure for Pr...re-USNewswire/ -- For parents of children with can...ates have steadily improved for decades. Among the... cause infertility. ,, Boys diagnosed with ca...portunity to preserve their fertility: before unde...
Breaking Medicine News(10 mins):Health News:Health Connect Partners Hosts Hospital O.R. & Surgery Center Conference 2Health News:Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan, Third Consecutive Year 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 2Health News:Mayo Researchers Find Robotic Repair for Vaginal Prolapse Has Significant Benefits 3Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 2Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 3Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 4
...lood volume explains it , , TUESDAY, Nov. ...ve learned that they need to adjust the results of...in obese men, but now researchers think they know ...new study doesn,t definitively prove why overweigh...
...ressure, more weight loss, study finds , ,...tart a walking program for their health get more o...s their steps, a new study shows. , "People who us...ntist at Stanford University. "They also seem to l...
...nth, ARLINGTON, Va., Nov. 20 Thanks to homecare,...t the U.S. will celebrate,Thanksgiving and other h...r,homes. During November, which is National Homeca...ically sound,cost-effective care in a patient-pref...
...each children how to keep hands clean, MORRIS PLA...uts a hand in his/her nose or mouth. Considering t...r longer on surfaces like,cafeteria tables, doorkn... for Disease Control and Prevention (CDC),keeping ...
...R, Nov. 20 /PRNewswire-FirstCall/ - Cardiome Pharm...itiation of subject dosing in its,Phase 1 study of...ose-ranging study will measure the safety, tolerab... 24-hour continuous,intravenous infusion of GED-aP...
...on Optics,Corporation, Inc. (OTC Bulletin Board: P...sults on an unaudited basis for the first quarter ...st Quarter Operating Results Revenues -- Total re...ts the second highest quarterly revenue in six,yea...
Other Medicine News:Health News:Why Obese Men Post Lower PSA Levels 2Health News:Pedometer Pushes People to Walk More 2Health News:Thanks to Homecare, Millions of Older Americans Celebrate Thanksgiving and Other Holidays at Home 2Health News:Proper Hand Hygiene Is Key to Avoiding Illness During Cold and Flu Season 2Health News:Cardiome Initiates Phase 1 Study for GED-aPC 2Health News:Cardiome Initiates Phase 1 Study for GED-aPC 3Health News:Cardiome Initiates Phase 1 Study for GED-aPC 4Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 2Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 3Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 4Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 5Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 6
Premier Encore Mini C-Arm
KM-500 Hand-Held Auto Keratometer
Herrick Lacrimal Plugs
Khosla Cryo Ultra
Medicine Products: